Dry Eye Disease Market Size was valued ~4 billion in 2023 to grow from 2024 to 2034, DelveInsight Reports | Alcon/Aerie Pharma, Mitotech, BRIM Biotechnology, Taejoon Pharma, Allysta Pharma

The Dry Eye Disease Market Forecast-2034 report offers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye Disease market trends in the 7MM.
DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Dry Eye Disease, offering comprehensive insights into the Dry Eye Disease revenue trends, prevalence, and treatment landscape. The report delves into key Dry Eye Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Dry Eye Disease therapies. Additionally, we cover the landscape of Dry Eye Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Dry Eye Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Dry Eye Disease space.

To Know in detail about the Dry Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dry Eye Disease Market Forecast [https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Dry Eye Disease Market Report:

*
The Dry Eye Disease market size was valued ~USD 4 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In 2023, the Dry Eye Disease (DED) market size in the EU4 and the UK was USD 821 million, with expectations of substantial growth at a notable CAGR.

*
In the 7MM, Japan held the third-largest market share, amounting to USD 199 million in 2023.

*
Key Dry Eye Disease Companies: Alcon/Aerie Pharmaceuticals, Mitotech, BRIM Biotechnology, Inc., Taejoon Pharmaceutical Co., Ltd, Allysta Pharmaceutical, Invirsa, Inc., Ocugen, Invirsa, Inc., Oculis, Telios Pharma, Inc., ORA, Inc., IVIEW Therapeutics, Senju Pharmaceutical, and others

*
Key Dry Eye Disease Therapies: AR-15512, SkQ1 eye drops, BRM421, TJO-083, ALY688, INV-102, Brimonidine, licaminlimab, TL-925, ST-100 (vezocolmitide), IVW-1001, LME636, SJP-0132, and others

*
The Dry Eye Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Eye Disease pipeline products will significantly revolutionize the Dry Eye Disease market dynamics.

*
In January 2024, Alcon, based in Switzerland, announced that its dry eye disease medication AR-15512 met its primary endpoints in two Phase III trials, COMET-2 and COMET-3. Following these positive results, the company intends to submit a New Drug Application (NDA) for AR-15512 to the FDA by mid-2024, as stated in a press release on January 9. The COMET-2 (NCT05285644) and COMET-3 (NCT05360966) trials, which were vehicle-controlled, included over 930 patients aged 30 and older with dry eye disease.

*
In April 2024, Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical firm specializing in pioneering medications that target the melanocortin receptor system, has announced the presentation of topline results from its Phase 3 PL9643 MELODY-1 trial. This pivotal study assesses the safety and effectiveness of PL9643 compared to a vehicle in treating dry eye disease (DED). The results were showcased at the American Society of Cataract and Refractive Surgery (ASCRS).

*
According to DelveInsight's assessment, the estimated total diagnosed prevalent cases of Dry Eye Disease across the 7MM were approximately 54.7 million in 2023.

*
In 2023, among European countries, the United Kingdom reported the highest number of diagnosed prevalent cases of Dry Eye Disease, with approximately 6.1 million cases, followed by Germany with about 5.0 million cases. Conversely, Spain had the lowest number of prevalent cases, totaling around 2.1 million.

*
The US had the highest proportion of total diagnosed prevalent cases of Dry Eye Disease among the 7MM countries in 2023, accounting for 41%, while Japan reported the lowest at 19%. This trend is expected to continue throughout the forecast period.

*
In the US, diagnosed prevalent cases of Dry Eye Disease were approximately 9,439 thousand for males and about 13,035 thousand for females in 2023. Projections suggest that by 2034, the prevalence among females will exceed that of males.

Dry Eye Disease Overview

Dry Eye Disease (DED) is a common condition where the eyes do not produce enough tears or the tears evaporate too quickly, leading to dryness, irritation, and inflammation. Symptoms often include a feeling of dryness or grittiness in the eyes, redness, blurred vision, and discomfort. Causes can range from environmental factors and medications to underlying health conditions. Treatment typically involves using artificial tears, lifestyle changes, and, in more severe cases, prescription medications or surgical options.

Get a Free sample for the Dry Eye Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/dry-eye-disease-market-insights [https://www.delveinsight.com/report-store/dry-eye-disease-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dry Eye Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dry Eye Disease Epidemiology Segmentation:

The Dry Eye Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Diagnosed Prevalent Cases of DED in the 7MM

*
Gender-specific Diagnosed Prevalent Cases of DED in the 7MM

*
Age-specific Diagnosed Prevalent Cases of DED in the 7MM

*
Severity-specific Diagnosed Prevalent Cases of DED in the 7MM

Download the report to understand which factors are driving Dry Eye Disease epidemiology trends @ Dry Eye Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dry Eye Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dry Eye Disease market or expected to get launched during the study period. The analysis covers Dry Eye Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dry Eye Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dry Eye Disease Therapies and Key Companies

*
AR-15512: Alcon/Aerie Pharmaceuticals

*
SkQ1 eye drops: Mitotech

*
BRM421: BRIM Biotechnology, Inc.

*
TJO-083: Taejoon Pharmaceutical Co., Ltd

*
ALY688: Allysta Pharmaceutical

*
INV-102: Invirsa, Inc.

*
Brimonidine: Ocugen

*
INV-102: Invirsa, Inc.

*
licaminlimab: Oculis

*
TL-925: Telios Pharma, Inc.

*
ST-100 (vezocolmitide): ORA, Inc.

*
IVW-1001: IVIEW Therapeutics

*
LME636: Alcon

*
SJP-0132: Senju Pharmaceutical

Discover more about therapies set to grab major Dry Eye Disease market share @ Dry Eye Disease Treatment Landscape [https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dry Eye Disease Market Strengths

*
Dry eye is a highly prevalent condition, affecting a significant portion of the population, particularly with advancing age. This prompts a substantial need for methods of diagnosis, treatment, and management solutions.

*
Various treatment options for dry eye syndrome are available, including artificial tears, prescription drugs, eyelid hygiene products, and punctal plugs, allowing for tailored approaches to management.

Dry Eye Disease Market Opportunities

*
Increased public education campaigns can further raise awareness of dry eye and encourage people to seek help.

*
Collaboration among pharmaceutical companies, research institutions, and healthcare providers can facilitate the development of novel therapies and diagnostic tools for Dry Eye Disease.

Scope of the Dry Eye Disease Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Dry Eye Disease Companies: Alcon/Aerie Pharmaceuticals, Mitotech, BRIM Biotechnology, Inc., Taejoon Pharmaceutical Co., Ltd, Allysta Pharmaceutical, Invirsa, Inc., Ocugen, Invirsa, Inc., Oculis, Telios Pharma, Inc., ORA, Inc., IVIEW Therapeutics, Senju Pharmaceutical, and others

*
Key Dry Eye Disease Therapies: AR-15512, SkQ1 eye drops, BRM421, TJO-083, ALY688, INV-102, Brimonidine, licaminlimab, TL-925, ST-100 (vezocolmitide), IVW-1001, LME636, SJP-0132, and others

*
Dry Eye Disease Therapeutic Assessment: Dry Eye Disease current marketed and Dry Eye Disease emerging therapies

*
Dry Eye Disease Market Dynamics: Dry Eye Disease market drivers and Dry Eye Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Dry Eye Disease Unmet Needs, KOL's views, Analyst's views, Dry Eye Disease Market Access and Reimbursement

To know more about Dry Eye Disease companies working in the treatment market, visit @ Dry Eye Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Dry Eye Disease Market Report Introduction

2. Executive Summary for Dry Eye Disease

3. SWOT analysis of Dry Eye Disease

4. Dry Eye Disease Patient Share (%) Overview at a Glance

5. Dry Eye Disease Market Overview at a Glance

6. Dry Eye Disease Disease Background and Overview

7. Dry Eye Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Dry Eye Disease

9. Dry Eye Disease Current Treatment and Medical Practices

10. Dry Eye Disease Unmet Needs

11. Dry Eye Disease Emerging Therapies

12. Dry Eye Disease Market Outlook

13. Country-Wise Dry Eye Disease Market Analysis (2020-2034)

14. Dry Eye Disease Market Access and Reimbursement of Therapies

15. Dry Eye Disease Market Drivers

16. Dry Eye Disease Market Barriers

17. Dry Eye Disease Appendix

18. Dry Eye Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dry-eye-disease-market-size-was-valued-4-billion-in-2023-to-grow-from-2024-to-2034-delveinsight-reports-alconaerie-pharma-mitotech-brim-biotechnology-taejoon-pharma-allysta-pharma]
Phone: +14699457679
Address:27 Drydock Ave S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services



This release was published on openPR.